Oncology Expert Insights

Eric Whitman, MD, medical director, oncology service line, Atlantic Health System; Vishal Patel, MD, FAAD, FACMS, associate professor, dermatology and medicine, GW School of Medicine & Health Sciences, director, Cutaneous Oncology Program, GW Cancer Center

Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

ByEric Whitman, MD,Vishal A. Patel, MD, FAAD, FACMS

January 31st 2026

Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.

Komal Jhaveri, MD, FACP, breast medical oncologist, Memorial Sloan Kettering Cancer Center

ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

ByKomal Jhaveri, MD, FACP

January 31st 2026

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

ByBeth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Sikander Ailawadhi, MD

January 30th 2026

Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, discuss the ongoing development of subcutaneous isatuximab administration via an on-body injector for patients with multiple myeloma.

Aditya Bardia, MD, MPH, FASCO, director, Translational Research Integration, member, Signal Transduction and Therapeutics, UCLA Health Jonsson Comprehensive Cancer Center

ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

ByAditya Bardia, MD, MPH, FASCO

January 29th 2026

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

ByJohn O. Mascarenhas, MD

January 29th 2026

John O. Mascarenhas, MD, details the investigation of novel targeted therapies in patients with myeloproliferative neoplasms.

Joanna M. Rhodes, MD, MSCE, director, Lymphoma, systems head, Lymphoma, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health; Krish Patel, MD, director, Lymphoma Research, executive chair, Lymphoma Research Executive Committee, Sarah Cannon Research Institute

CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD

ByJoanna M. Rhodes, MD, MSCE,Krish Patel, MD

December 31st 2025

Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.

Osimertinib Carves a Continuing Role in Perioperative NSCLC Management: With Julia Rotow, MD; and Gavitt Woodard, MD

ByGavitt Woodard, MD,Julia Rotow, MD

December 29th 2025

Drs Rotow and Woodard talk through recent updates to the perioperative non–small cell lung cancer treatment paradigm.

MRI Techniques Evolve for Glioma Diagnosis, Response Assessment, and Surveillance: With Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD

ByKathryn S. Nevel, MD,Michael Veronesi, MD, PhD

December 25th 2025

Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD, lead an OncLive Ask the Expert discussion on evolving imaging strategies in glioma.

Jason Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

ctDNA Testing Opens Avenues for the Future of Breast Oncology: With Jason Mouabbi, MD

ByJason Mouabbi, MD

December 22nd 2025

Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.

Gregory J. Tiesi, MD, FACS, FSSO, medical director, Hepatobiliary Surgery, Hackensack Meridian Jersey Shore University Medical Center; Anthony Scholer, MD, FACS, FSSO, surgical oncologist, hepatobiliary surgery, Hackensack Meridian Medical Group and Jersey Shore University Medical Center; Benjamin Jon Golas, MD, FACS, regional chief, Surgical Oncology, Hackensack Meridian Health’s Central Region, surgical director, Oncology Services, Jersey Shore University Medical Center, vice chair, Surgery, Jersey Shore University Medical Center Cancer Surgery, associate professor, surgery, Hackensack Meridian School of Medicine; Eric Pletcher, MD, surgeon, Complex General Surgical Oncology, Hackensack Meridian JFK University Medical Center

Hepatic Artery Infusion Refines Liver-Directed Care for GI Cancers: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

ByGregory J. Tiesi, MD, FACS, FSSO,Anthony Scholer, MD, FACS, FSSO,Benjamin Jon Golas, MD, FACS,Eric Pletcher, MD

December 9th 2025

Drs Tiesi, Scholer, Golas, and Pletcher discuss the use of hepatic artery infusion in colon cancer and liver cancer management.

PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

ByGregory J. Tiesi, MD, FACS, FSSO,Anthony Scholer, MD, FACS, FSSO,Benjamin Jon Golas, MD, FACS,Eric Pletcher, MD

December 3rd 2025

Drs Tiesi, Scholer, Golas, and Pletcher discussed the use of PIPAC, a minimally invasive regional cancer therapy, in patients with peritoneal cancers.

Sarah Rutherford, MD, associate professor, clinical medicine, Division of Hematology/Oncology, Weill Cornell Medicine

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

BySarah Rutherford, MD

December 3rd 2025

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

Shubham Pant, MD, MBBS, professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, director, Clinical Research, professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

ByShubham Pant, MD, MBBS

December 2nd 2025

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Jacob Sands, MD, associate chief, Lowe Center for Thoracic Oncology, Oncology Medical Director, International Patient Center, Dana-Farber Cancer Institute, assistant professor, Harvard Medical School; Shailee Shah, MD, clinical assistant professor, neurology (MS/neuroimmunology) North,western University Feinberg School of Medicine

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

ByJacob Sands, MD,Shailee S. Shah, MD

December 1st 2025

Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.

Joshua Richter, MD, associate professor, medicine, The Tisch Cancer Institute; director, Multiple Myeloma, Blavatnik Family Chelsea Medical Center, Mount Sinai

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

ByJoshua Richter, MD

November 28th 2025

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Cassie Kline, MD, MAS, attending physician, director, Clinical Research, Department of Neuro-Oncology, Children's Hospital of Philadelphia

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

ByCassie Kline, MD, MAS

November 27th 2025

Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.

Martha K. Terris, MD, FACS, department chair, professor, Department of Urology, Witherington Distinguished Chair in Urology, co-director, Cancer Center, Medical College of Georgia at Augusta University

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 18th 2025

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

Benjamin P. Levy, MD Kamel Abou Hussein, MD Victoria Rizk, MD

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

ByBenjamin P. Levy, MD,Victoria Rizk, MD,Kamel Abou Hussein, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 11th 2025

Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.

Kevin Kalinsky, MD, MS, FASCO, professor, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; director, Glenn Family Breast Center, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Winship Cancer Institute

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

ByKevin Kalinsky, MD, MS

November 7th 2025

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

Stephen Liu, MD, associate professor, medicine, Georgetown University; director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

ByStephen Liu, MD

November 6th 2025

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, professor, medicine, Mayo Clinic; Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO nurse practitioner, Multiple Myeloma Program, Cleveland Clinic

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

BySikander Ailawadhi, MD,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

November 5th 2025

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

ByNeal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Ziad Hanhan, MD, thoracic surgeon, Hackensack Meridian Health, chairman, Surgery at Bayshore Medical Center, chief, Thoracic Surgery, Riverview Medical Center; Thomas Bauer, MD, chair, surgery, Jersey Shore University Medical Center and Hackensack Meridian Health School of Medicine; Rachel NeMoyer, MD, thoracic surgeon, Hackensack Meridian Health

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

ByZiad Hanhan, MD,Thomas Bauer, MD,Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

ByAmit Mehta, MD

October 29th 2025

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Eunice Wang, MD, professor, oncology, leader, Leukemia Clinical Disease Team, chief, leukemia, Department of Medicine, assistant member, Tumor Immunology Program, Department of Immunology, Roswell Park Comprehensive Cancer Center; associate professor, Department of Medicine, academic scholar, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

ByEunice Wang, MD

October 22nd 2025

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Kanwal P. S. Raghav, MBBS, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine; associate vice president, Department of Ambulatory Medical Operations; executive medical director, Department of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

ByKanwal Raghav, MBBS, MD

October 6th 2025

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD

ByStephen Liu, MD

October 1st 2025

Dr Liu discusses the 2 VISION trial of tepotinib for NSCLC harboring MET exon 14 skipping alterations, as well as the importance of biomarker testing.

Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD

ByAndrew Kuykendall, MD

September 29th 2025

Andrew Kuykendall, MD, provides an overview of the myelofibrosis treatment paradigm.

Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD

ByKohei Shitara, MD, National Cancer Center Hospital East

September 25th 2025

Kohei Shitara, MD, discusses optimizing treatment strategies and addressing unmet needs in resectable gastric and gastroesophageal junction cancers.